Genetic insights into drug targets for alzheimer’s disease: integrative multi-omics analysis
Open Access
- 5 December 2025
- journal article
- research article
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 17 (1) , 258
Abstract
The development of effective disease-modifying therapies for Alzheimer’s disease (AD) remains a critical unmet need. While Mendelian randomization (MKeywords
This publication has 78 references indexed in Scilit:
- 2024 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2024
- Systematic druggable genome‐wide Mendelian randomization identifies therapeutic targets for sarcopeniaJournal of Cachexia, Sarcopenia and Muscle, 2024
- Alzheimer's disease drug development pipeline: 2023Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2023
- Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkersActa Neuropathologica, 2022
- Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease?Alzheimer's & Dementia, 2022
- Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian RandomizationJAMA, 2021
- The Genetic Architecture of Depression in Individuals of East Asian AncestryJAMA Psychiatry, 2021
- APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer’s diseaseActa Neuropathologica, 2020
- Senescent cells: Living or dying is a matter of NK cellsJournal of Leukocyte Biology, 2019
- APOE genotype alters glial activation and loss of synaptic markers in miceGlia, 2012